Deborah H. Telman - 25 Oct 2025 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
27 Oct 2025, 19:43:51 UTC
Prior SEC filing
11 Sep 2025
Next SEC filing
13 Nov 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Edward S. Son by Power of Attorney for Deborah H. Telman

Key filing fact

Deborah H. Telman filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 27 Oct 2025.

Key facts

  • This page summarizes Deborah H. Telman's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 27 Oct 2025, 19:43.

Change

  • Previous filing in this sequence was filed on 11 Sep 2025.
  • Current net transaction value: -$29,147.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001860008 Primary reporting owner

Telman Deborah H

Relationship
EVP, Corporate Affairs & GC
Address
GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY
Signature
/s/ Edward S. Son by Power of Attorney for Deborah H. Telman
Signature date
27 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GILD transaction

Common Stock

Options Exercise

Transaction value
Shares
+515
Change %
+1.2%
Price
Shares after
43,917
Date
25 Oct 2025
Ownership
Direct
Footnotes
F1
GILD transaction

Common Stock

Tax liability

Transaction value
$29,147
Shares
-241
Change %
-0.55%
Price
$120.94
Shares after
43,676
Date
25 Oct 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GILD transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares
-515
Change %
-2.5%
Price
Shares after
19,816
Date
25 Oct 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
515
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Footnote F2

The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .